Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny
Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.
Pharma & Biotech
Pharma & Biotech
Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
Pharma & Biotech
Enliven Therapeutics moves closer to Phase 3 as ELVN-001 faces its real test
ELVN-001 has early CML promise and a long cash runway. Phase 3 execution now decides whether Enliven Therapeutics can justify the hype.
Pharma & Biotech
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.
Pharma & Biotech
Can Idorsia Pharmaceuticals Ltd’s lucerastat redefine Fabry disease treatment beyond enzyme replacement therapy?
Discover how Idorsia Pharmaceuticals Ltd’s FDA-aligned Phase 3 plan could make lucerastat the first oral therapy for all Fabry disease patients. Read the analysis.
Pharma & Biotech
Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Pharma & Biotech
What Cloudbreak Pharma’s Phase 2 FDA meeting reveals about late-stage risk in ophthalmic drug development
Find out how Cloudbreak Pharma’s Phase 2 FDA meeting reshapes late-stage risk for CBT-004 and what it signals for ophthalmic drug development.
Pharma & Biotech
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.
Pharma & Biotech
Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope
Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double
Pharma & Biotech
Sobi bets $950m on Arthrosi to reshape chronic gout treatment with pozdeutinurad
Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise.